Together, our study provides relevant information about the contribution of CD1c+ cDC to cellular networks participating in RA pathogenesis and identifies crosstalk between the NLRC4 inflammasome and CD64 as potential future therapeutic targets for CD1c+ cDC in patients with RA. Here, FCGR1A is linked to rheumatoid arthritis.